Thank you.
There are two exciting technologies. For example, both the Moderna and Pfizer vaccines are mRNA vaccines, which existed before for cancer therapy in other products. Even the adenoviral vectors that are being used by J&J and AstraZeneca were previous technologies that existed. COVID leapfrogged them forward because of, unfortunately, the increased demand—the increased demand politically for our economy, and also for volume.
It's a good-news, bad-news story. The bad-news story is COVID. The good-news story is that now we have two new technologies that can be applied to infectious diseases, including HIV. We can apply them to cancers, things that in the past didn't get the funding and support for these breakthrough technologies. It is actually an exciting time from a medical technology perspective, even if it was created for the wrong reasons, given this pandemic. It was for the right reasons—you know what I mean—but it was the wrong motivator, because it should have been done probably five to 10 years ago and should have had that funding back then.